Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
Portfolio Pulse from
Relmada Therapeutics announced that the Phase 3 Reliance II trial for their CNS drug is deemed futile by the Data Monitoring Committee, indicating it is unlikely to meet its primary efficacy endpoint. Despite this setback, Relmada will focus on developing REL-P11 for metabolic disease and has $54.1 million in cash reserves.
December 04, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Relmada Therapeutics' Phase 3 Reliance II trial is unlikely to meet its primary efficacy endpoint, as per the DMC. The company will now focus on REL-P11 for metabolic disease, with $54.1 million in cash reserves.
The futility of the Phase 3 Reliance II trial is a significant setback for Relmada, likely leading to a negative short-term impact on its stock price. However, the company's focus on REL-P11 and its strong cash position may mitigate some concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100